Mehan S, Kumar A, Utage PR, et al. Efficacy and Safety of Altibrain® as an Adjunctive Therapy for Autism Spectrum Disorder: An Open Label Trial Targeting Core Symptoms. Curr Pharm Des. Published online January 24, 2025. doi:10.2174/0113816128335544241210144541
Kumar M, Mehan S, Kumar A, Sharma T, Khan Z, Tiwari A, Das Gupta G, Narula AS. Therapeutic efficacy of Genistein in activation of neuronal AC/cAMP/CREB/PKA and mitochondrial ETC-Complex pathways in experimental model of autism: Evidence from CSF, blood plasma and brain analysis. Brain Res. 2024 Oct 7:149251. doi: 10.1016/j.brainres.2024.149251. Epub ahead of print. PMID: 39384128.
Dhiman A, Mehan S, Khan Z, Tiwari A, Gupta GD, Narula AS. Hereditary Patterns and Genetic Associations in Obsessive-Compulsive Disorder (OCD): Neuropsychiatric Insights, Genetic Influences, and Treatment Perspectives. Curr Gene Ther. 2024 Aug 30. doi: 10.2174/0115665232316708240828063527. Epub ahead of print. PMID: 39219434.
Giri A, Mehan S, Khan Z, Gupta GD, Narula AS. Melatonin-mediated IGF-1/GLP-1 activation in experimental OCD rats: Evidence from CSF, blood plasma, brain and in-silico investigations. Biochem Pharmacol. 2023;217:115831. doi:10.1016/j.bcp.2023.115831
Sethi P, Mehan S, Khan Z, Chhabra S. Acetyl-11-keto-beta boswellic acid(AKBA) modulates CSTC-pathway by activating SIRT-1/Nrf2-HO-1 signalling in experimental rat model of obsessive-compulsive disorder: Evidenced by CSF, blood plasma and histopathological alterations. Neurotoxicology. 2023 Aug 5;98:61-85. doi: 10.1016/j.neuro.2023.08.001. Epub ahead of print. PMID: 37549874.
Bhalla S, Mehan S. 4-hydroxyisoleucine mediated IGF-1/GLP-1 signalling activation prevents propionic acid-induced autism-like behavioural phenotypes and neurochemical defects in experimental rats. Neuropeptides. 2022 Dec;96:102296. doi: 10.1016/j.npep.2022.102296. Epub 2022 Oct 20. PMID: 36307249.
Gupta R, Mehan S, Chhabra S, Giri A, Sherawat K. Role of Sonic Hedgehog Signaling Activation in the Prevention of Neurological Abnormalities Associated with Obsessive-Compulsive Disorder. Neurotox Res. 2022 Dec;40(6):1718-1738. doi: 10.1007/s12640-022-00586-4. Epub 2022 Oct 22. PMID: 36272053.
Rajkhowa B, Mehan S, Sethi P, Prajapati A, Suri M, Kumar S, Bhalla S, Narula AS, Alshammari A, Alharbi M, Alkahtani N, Alghamdi S, Kalfin R. Activating SIRT-1 Signalling with the Mitochondrial-CoQ10 Activator Solanesol Improves Neurobehavioral and Neurochemical Defects in Ouabain-Induced Experimental Model of Bipolar Disorder. Pharmaceuticals (Basel). 2022 Aug 2;15(8):959. doi: 10.3390/ph15080959. PMID: 36015107; PMCID: PMC9415079.
Sharma A, Bhalla S, Mehan S. PI3K/AKT/mTOR signalling inhibitor chrysophanol ameliorates neurobehavioural and neurochemical defects in propionic acid-induced experimental model of autism in adult rats. Metab Brain Dis. 2022 Aug;37(6):1909-1929. doi: 10.1007/s11011-022-01026-0. Epub 2022 Jun 10. PMID: 35687217.
Rahi S, Mehan S. Understanding Abnormal SMO-SHH Signaling in Autism Spectrum Disorder: Potential Drug Target and Therapeutic Goals. Cell Mol Neurobiol. 2022 May;42(4):931-953. doi: 10.1007/s10571-020-01010-1. Epub 2020 Nov 18. PMID: 33206287.
Rajkhowa B, Mehan S, Sethi P, Prajapati A. Activation of SIRT-1 Signalling in the Prevention of Bipolar Disorder and Related Neurocomplications: Target Activators and Influences on Neurological Dysfunctions. Neurotox Res. 2022 Apr;40(2):670-686. doi: 10.1007/s12640-022-00480-z. Epub 2022 Feb 14. PMID: 35156173.
Gupta R, Mehan S, Sethi P, Prajapati A, Alshammari A, Alharbi M, Al-Mazroua HA, Narula AS. Smo-Shh Agonist Purmorphamine Prevents Neurobehavioral and Neurochemical Defects in 8-OH-DPAT-Induced Experimental Model of Obsessive-Compulsive Disorder. Brain Sci. 2022 Mar 2;12(3):342. doi: 10.3390/brainsci12030342. PMID: 35326298; PMCID: PMC8946713.
Rahi S, Gupta R, Sharma A, Mehan S. Smo-Shh signaling activator purmorphamine ameliorates neurobehavioral, molecular, and morphological alterations in an intracerebroventricular propionic acid-induced experimental model of autism. Hum Exp Toxicol. 2021 Nov;40(11):1880-1898. doi: 10.1177/09603271211013456. Epub 2021 Apr 28. PMID: 33906504.
Sharma A, Mehan S. Targeting PI3K-AKT/mTOR signaling in the prevention of autism. Neurochem Int. 2021 Jul;147:105067. doi: 10.1016/j.neuint.2021.105067. Epub 2021 May 13. PMID: 33992742.
Tiwari A, Khera R, Rahi S, Mehan S, Makeen HA, Khormi YH, Rehman MU, Khan A. Neuroprotective Effect of α-Mangostin in the Ameliorating Propionic Acid-Induced Experimental Model of Autism in Wistar Rats. Brain Sci. 2021 Feb 25;11(3):288. doi: 10.3390/brainsci11030288. PMID: 33669120; PMCID: PMC7996534.
Tiwari A, Rahi S, Mehan S. Elucidation of Abnormal Extracellular Regulated Kinase (ERK) Signaling and Associations with Syndromic and Non-syndromic Autism. Curr Drug Targets. 2021;22(9):1071-1086. doi: 10.2174/1389450121666201020155010. PMID: 33081671.
Sharma R, Rahi S, Mehan S. Neuroprotective potential of solanesol in intracerebroventricular propionic acid induced experimental model of autism: Insights from behavioral and biochemical evidence. Toxicol Rep. 2019 Nov 5;6:1164-1175. doi: 10.1016/j.toxrep.2019.10.019. PMID: 31763180; PMCID: PMC6861559.
Sharma, Ramit & Tiwari, Aarti & Rahi, Saloni & Mehan, Sidharth. (2020). Current Neuropharmacological Interventions in Autism: Potential Drug Targets from Pre-clinical and Clinical Findings. Current Psychopharmacology. 09. 10.2174/1389203721999200820165117.
Files coming soon.
Multiple sclerosis
Sharma A, Sharma N, Khanna K, Arora A, Mehan S, Sharma A. Enhancing therapeutic efficacy of Fingolimod via Intranasal Delivery in an Ethidium Bromide-induced Model of Multiple Sclerosis. J Neurosci Methods. Published online March 7, 2025. doi:10.1016/j.jneumeth.2025.110415
Kumar N, Tyagi N, Mehan S, Singh AP. Enhanced Neuroprotection in Experiment Multiple Sclerosis through Combined Rosiglitazone and Probiotic-Loaded Solid Lipid Nanoparticles: Modulation of Cellular Signaling Pathways. CNS Neurol Disord Drug Targets. 2024 Nov 1. doi: 10.2174/0118715273336107241015100912. Epub ahead of print. PMID: 39492769.
Sharma T, Mehan S, Tiwari A, Khan Z, Gupta GD, Narula AS. Targeting Oligodendrocyte Dynamics and Remyelination: Emerging Therapies and Personalized Approaches in Multiple Sclerosis Management. Curr Neurovasc Res. 2024 Aug 30. doi: 10.2174/0115672026336440240822063430. Epub ahead of print. PMID: 39219420.
Khan Z, Mehan S, Gupta GD, Narula AS. Immune System Dysregulation in the Progression of Multiple Sclerosis: Molecular Insights and Therapeutic Implications. Neuroscience. Published online April 30, 2024. doi:10.1016/j.neuroscience.2024.04.004
Prajapati A, Mehan S, Khan Z, Chhabra S, Das Gupta G. Purmorphamine, a Smo-Shh/Gli Activator, Promotes Sonic Hedgehog-Mediated Neurogenesis and Restores Behavioural and Neurochemical Deficits in Experimental Model of Multiple Sclerosis. Neurochem Res. Published online December 30, 2023. doi:10.1007/s11064-023-04082-9
Khan Z, Gupta GD, Mehan S. Cellular and Molecular Evidence of Multiple Sclerosis Diagnosis and Treatment Challenges. J Clin Med. 2023 Jun 26;12(13):4274. doi: 10.3390/jcm12134274. PMID: 37445309; PMCID: PMC10342392.
Mehan S. Editorial: Therapeutic modulators inhibiting neuromuscular and motor neuron degeneration. Front Neurosci. 2023 Apr 6;17:1188945. doi: 10.3389/fnins.2023.1188945. PMID: 37090793; PMCID: PMC10116609.
Kapoor T, Mehan S, Suri M, Sharma N, Kumar N, Narula AS, Alshammari A, Alasmari AF, Alharbi M, Assiri MA, Kalfin R. Forskolin, an Adenylcyclase/cAMP/CREB Signaling Activator Restoring Myelin-Associated Oligodendrocyte Destruction in Experimental Ethidium Bromide Model of Multiple Sclerosis. Cells. 2022 Sep 6;11(18):2771. doi: 10.3390/cells11182771. PMID: 36139346; PMCID: PMC9497421.
Kumar N, Sahoo NK, Mehan S, Verma B. The importance of gut-brain axis and use of probiotics as a treatment strategy for multiple sclerosis. Mult Scler Relat Disord. 2023 Mar;71:104547. doi: 10.1016/j.msard.2023.104547. Epub 2023 Feb 2. PMID: 36805171.
Upadhayay S, Mehan S, Prajapati A, Sethi P, Suri M, Zawawi A, Almashjary MN, Tabrez S. Nrf2/HO-1 Signaling Stimulation through Acetyl-11-Keto-Beta-Boswellic Acid (AKBA) Provides Neuroprotection in Ethidium Bromide-Induced Experimental Model of Multiple Sclerosis. Genes (Basel). 2022 Jul 25;13(8):1324. doi: 10.3390/genes13081324. PMID: 35893061; PMCID: PMC9331916.
Khera R, Mehan S, Bhalla S, Kumar S, Alshammari A, Alharbi M, Sadhu SS. Guggulsterone Mediated JAK/STAT and PPAR-Gamma Modulation Prevents Neurobehavioral and Neurochemical Abnormalities in Propionic Acid-Induced Experimental Model of Autism. Molecules. 2022 Jan 28;27(3):889. doi: 10.3390/molecules27030889. PMID: 35164154; PMCID: PMC8839522.
Singh A, Upadhayay S, Mehan S. Understanding Abnormal c-JNK/p38MAPK Signaling Overactivation Involved in the Progression of Multiple Sclerosis: Possible Therapeutic Targets and Impact on Neurodegenerative Diseases. Neurotox Res. 2021 Oct;39(5):1630-1650. doi: 10.1007/s12640-021-00401-6. Epub 2021 Aug 25. PMID: 34432262.
Upadhayay, Shubham & Mehan, Sidharth. (2021). Targeting Nrf2/HO-1 anti-oxidant signaling pathway in the progression of multiple sclerosis and influences on neurological dysfunctions. Brain Disorders. 3. 100019. 10.1016/j.dscb.2021.100019.
Kumar N, Sharma N, Khera R, Gupta R, Mehan S. Guggulsterone ameliorates ethidium bromide-induced experimental model of multiple sclerosis via restoration of behavioral, molecular, neurochemical and morphological alterations in rat brain. Metab Brain Dis. 2021 Jun;36(5):911-925. doi: 10.1007/s11011-021-00691-x. Epub 2021 Feb 26. PMID: 33635478.
Sharma N, Shandilya A, Kumar N, Mehan S. Dysregulation of SIRT-1 Signaling in Multiple Sclerosis and Neuroimmune Disorders: A Systematic Review of SIRTUIN Activators as Potential Immunomodulators and their Influences on other Dysfunctions. Endocr Metab Immune Disord Drug Targets. 2021;21(10):1845-1868. doi: 10.2174/1871530321666210309112234. PMID: 33687904.
Kapoor T, Mehan S. Neuroprotective Methodologies in the Treatment of Multiple Sclerosis Current Status of Clinical and Pre-clinical Findings. Curr Drug Discov Technol. 2021;18(1):31-46. doi: 10.2174/1570163817666200207100903. PMID: 32031075.
Singh, Anshuman & Upadhayay, Shubham & Mehan, Sidharth. (2021). Inhibition of c-JNK/p38MAPK signaling pathway by Apigenin prevents neurobehavioral and neurochemical defects in ethidium bromide-induced experimental model of multiple sclerosis in rats: Evidence from CSF, blood plasma and brain samples. Phytomedicine Plus. 1. 100139. 10.1016/j.phyplu.2021.100139.
Sharma R, Khan Z, Mehan S, Das Gupta G, Narula AS. Unraveling the Multifaceted Insights into Amyotrophic Lateral Sclerosis: Genetic Underpinnings, Pathogenesis, and Therapeutic Horizons. Mutat Res Rev Mutat Res. 2024 Nov 2:108518. doi: 10.1016/j.mrrev.2024.108518. Epub ahead of print. PMID: 39491718.
Sharma R, Mehan S, Khan Z, Das Gupta G, Narula AS. Therapeutic potential of oleanolic acid in modulation of PI3K/Akt/mTOR/STAT-3/GSK-3β signaling pathways and neuroprotection against methylmercury-induced neurodegeneration. Neurochem Int. 2024 Oct 3;180:105876. doi: 10.1016/j.neuint.2024.105876. Epub ahead of print. PMID: 39368746.
Sharma, S., Mehan, S., Khan, Z., Gupta, G. D., & Narula, A. S. (2024). Icariin prevents methylmercury-induced experimental neurotoxicity: Evidence from cerebrospinal fluid, blood plasma, brain samples, and in-silico investigations. Heliyon, 10(1), e24050. https://doi.org/10.1016/j.heliyon.2024.e24050
Kumar S, Mehan S, Khan Z, Das Gupta G, Narula AS. Guggulsterone Selectively Modulates STAT-3, mTOR, and PPAR-Gamma Signaling in a Methylmercury-Exposed Experimental Neurotoxicity: Evidence from CSF, Blood Plasma, and Brain Samples. Mol Neurobiol. Published online January 3, 2024. doi:10.1007/s12035-023-03902-x
Shandilya A, Mehan S, Kumar S, Sethi P, Narula AS, Alshammari A, Alharbi M, Alasmari AF. Activation of IGF-1/GLP-1 Signalling via 4-Hydroxyisoleucine Prevents Motor Neuron Impairments in Experimental ALS-Rats Exposed to Methylmercury-Induced Neurotoxicity. Molecules. 2022 Jun 16;27(12):3878. doi: 10.3390/molecules27123878. PMID: 35745001; PMCID: PMC9228431.
Sahu R, Mehan S, Kumar S, Prajapati A, Alshammari A, Alharbi M, Assiri MA, Narula AS. Effect of alpha-mangostin in the prevention of behavioural and neurochemical defects in methylmercury-induced neurotoxicity in experimental rats. Toxicol Rep. 2022 Apr 22;9:977-998. doi: 10.1016/j.toxrep.2022.04.023. PMID: 35783250; PMCID: PMC9247835.
Yadav RK, Mehan S, Sahu R, Kumar S, Khan A, Makeen HA, Al Bratty M. Protective effects of apigenin on methylmercury-induced behavioral/neurochemical abnormalities and neurotoxicity in rats. Hum Exp Toxicol. 2022 Jan-Dec;41:9603271221084276. doi: 10.1177/09603271221084276. PMID: 35373622.
Minj E, Upadhayay S, Mehan S. Nrf2/HO-1 Signaling Activator Acetyl-11-keto-beta Boswellic Acid (AKBA)-Mediated Neuroprotection in Methyl Mercury-Induced Experimental Model of ALS. Neurochem Res. 2021 Nov;46(11):2867-2884. doi: 10.1007/s11064-021-03366-2. Epub 2021 Jun 1. PMID: 34075522.
Sahu R, Upadhayay S, Mehan S. Inhibition of extracellular regulated kinase (ERK)-1/2 signaling pathway in the prevention of ALS: Target inhibitors and influences on neurological dysfunctions. Eur J Cell Biol. 2021 Sep-Nov;100(7-8):151179. doi: 10.1016/j.ejcb.2021.151179. Epub 2021 Sep 17. PMID: 34560374.
Shandilya A, Mehan S. Dysregulation of IGF-1/GLP-1 signaling in the progression of ALS: potential target activators and influences on neurological dysfunctions. Neurol Sci. 2021 Aug;42(8):3145-3166. doi: 10.1007/s10072-021-05328-6. Epub 2021 May 21. PMID: 34018075.
Yadav RK, Minz E, Mehan S. Understanding Abnormal c-JNK/p38MAPK Signaling in Amyotrophic Lateral Sclerosis: Potential Drug Targets and Influences on Neurological Disorders. CNS Neurol Disord Drug Targets. 2021;20(5):417-429. doi: 10.2174/1871527320666210126113848. PMID: 33557726.
Minj E, Yadav RK, Mehan S. Targeting Abnormal Nrf2/HO-1 Signaling in Amyotrophic Lateral Sclerosis: Current Insights on Drug Targets and Influences on Neurological Disorders. Curr Mol Med. 2021;21(8):630-644. doi: 10.2174/1566524021666210111104920. PMID: 33430731.
Alam M, Yadav RK, Minj E, Tiwari A, Mehan S. Exploring Molecular Approaches in Amyotrophic Lateral Sclerosis: Drug Targets from Clinical and Pre-Clinical Findings. Curr Mol Pharmacol. 2021;14(3):263-280. doi: 10.2174/1566524020666200427214356. PMID: 32342825.
Mamtaj, Mohmmad & Minj, Elizabeth & Yadav, Rajeshwar & Mehan, Sidharth. (2020). Neuroprotective Potential of Adenyl Cyclase/cAMP/CREB and Mitochondrial CoQ10 Activator in Amyotrophic Lateral Sclerosis Rats. Current Bioactive Compounds. 16. 10.2174/1573407216999200723113054.
Files coming soon.
Alzheimer's, Parkinson's, Huntington's
Khan MS, Khan Z, Jabir NR, Mehan S, Suhail M, Zaidi SK, Zughaibi TA, Abid M, Tabrez S. Synthesis and Neurobehavioral Evaluation of a Potent Multitargeted Inhibitor for the Treatment of Alzheimer's Disease. Mol Neurobiol. 2024 Jul 15. doi: 10.1007/s12035-024-04351-w. Epub ahead of print. PMID: 39009798.
Khan Z, Mehan S, Saifi MA, Gupta GD, Narula AS, Kalfin R. Proton Pump Inhibitors and Cognitive Health: Review on Unraveling the Dementia Connection and Co-morbid Risks. Curr Alzheimer Res. Published online February 28, 2024. doi:10.2174/0115672050289946240223050737
Nabi SU, Khan A, Siddiqui EM, Rehman MU, Alshahrani S, Arafah A, Mehan S, Alsaffar RM, Alexiou A, Shen B. Mechanisms of Mitochondrial Malfunction in Alzheimer's Disease: New Therapeutic Hope. Oxid Med Cell Longev. 2022 May 14;2022:4759963. doi: 10.1155/2022/4759963. PMID: 35607703; PMCID: PMC9124149.
Mehan S, Bhalla S, Siddiqui EM, Sharma N, Shandilya A, Khan A. Potential Roles of Glucagon-Like Peptide-1 and Its Analogues in Dementia Targeting Impaired Insulin Secretion and Neurodegeneration. Degener Neurol Neuromuscul Dis. 2022 Mar 7;12:31-59. doi: 10.2147/DNND.S247153. PMID: 35300067; PMCID: PMC8921673.
Alharbi M, Alshammari A, Kaur G, Kalra S, Mehan S, Suri M, Chhabra S, Kumar N, Alanazi WA, Alshanwani AR, Al-Ghamdi AH, Narula AS, Kalfin R. Effect of Natural Adenylcyclase/cAMP/CREB Signalling Activator Forskolin against Intra-Striatal 6-OHDA-Lesioned Parkinson's Rats: Preventing Mitochondrial, Motor and Histopathological Defects. Molecules. 2022 Nov 17;27(22):7951. doi: 10.3390/molecules27227951. PMID: 36432051; PMCID: PMC9695774.
Duggal P, Jadaun KS, Siqqiqui EM, Mehan S. Investigation of Low Dose Cabazitaxel Potential as Microtubule Stabilizer in Experimental Model of Alzheimer's Disease: Restoring Neuronal Cytoskeleton. Curr Alzheimer Res. 2020;17(7):601-615. doi: 10.2174/1567205017666201007120112. PMID: 33030130.
Duggal P, Mehan S. Neuroprotective Approach of Anti-Cancer Microtubule Stabilizers Against Tauopathy Associated Dementia: Current Status of Clinical and Preclinical Findings. J Alzheimers Dis Rep. 2019 Jul 2;3(1):179-218. doi: 10.3233/ADR-190125. PMID: 31435618; PMCID: PMC6700530.
Albekairi TH, Kamra A, Bhardwaj S, Mehan S, Giri A, Suri M, Alshammari A, Alharbi M, Alasmari AF, Narula AS, Kalfin R. Beta-Boswellic Acid Reverses 3-Nitropropionic Acid-Induced Molecular, Mitochondrial, and Histopathological Defects in Experimental Rat Model of Huntington's Disease. Biomedicines. 2022 Nov 9;10(11):2866. doi: 10.3390/biomedicines10112866. PMID: 36359390; PMCID: PMC9687177.
Kaur R, Mehan S, Singh S. Understanding multifactorial architecture of Parkinson's disease: pathophysiology to management. Neurol Sci. 2019 Jan;40(1):13-23. doi: 10.1007/s10072-018-3585-x. Epub 2018 Sep 29. PMID: 30267336.
Mehan S, Monga V, Rani M, Dudi R, Ghimire K. Neuroprotective effect of solanesol against 3-nitropropionic acid-induced Huntington's disease-like behavioral, biochemical, and cellular alterations: Restoration of coenzyme-Q10-mediated mitochondrial dysfunction. Indian J Pharmacol. 2018 Nov-Dec;50(6):309-319. doi: 10.4103/ijp.IJP_11_18. PMID: 30783323; PMCID: PMC6364342.
Mehan S, Meena H, Sharma D, Sankhla R. JNK: a stress-activated protein kinase therapeutic strategies and involvement in Alzheimer's and various neurodegenerative abnormalities. J Mol Neurosci. 2011 Mar;43(3):376-90. doi: 10.1007/s12031-010-9454-6. Epub 2010 Sep 28. PMID: 20878262.
Deshmukh R, Sharma V, Mehan S, Sharma N, Bedi KL. Amelioration of intracerebroventricular streptozotocin induced cognitive dysfunction and oxidative stress by vinpocetine -- a PDE1 inhibitor. Eur J Pharmacol. 2009 Oct 12;620(1-3):49-56. doi: 10.1016/j.ejphar.2009.08.027. Epub 2009 Aug 21. PMID: 19699735.
Files coming soon.
cellular & molecular target modulation in cns dysfunctions
Mukherjee R, Rana R, Mehan S, et al. Investigating the Interplay Between the Nrf2/Keap1/HO-1/SIRT-1 Pathway and the p75NTR/PI3K/Akt/MAPK Cascade in Neurological Disorders: Mechanistic Insights and Therapeutic Innovations. Mol Neurobiol. Published online February 7, 2025. doi:10.1007/s12035-025-04725-8
Choudhary D, Nasiruddin Khan MD, Khan Z, et al. Navigating the complexities of neuronal signaling and targets in neurological disorders: From pathology to therapeutics. Eur J Pharmacol. Published online February 25, 2025. doi:10.1016/j.ejphar.2025.177417
Gupta S, Gupta AK, Mehan S, Khan Z, Gupta GD, Narula AS. Disruptions in cellular communication: Molecular interplay between glutamate/NMDA signalling and MAPK pathways in neurological disorders. Neuroscience. 2025;569:331-353. doi:10.1016/j.neuroscience.2025.01.021
Sethi P, Mehan S, Khan Z, Maurya PK, Kumar N, Kumar A, Tiwari A, Sharma T, Das Gupta G, Narula AS, Kalfin R. The SIRT-1/Nrf2/HO-1 axis: Guardians of neuronal health in neurological disorders. Behav Brain Res. 2024 Oct 4;476:115280. doi: 10.1016/j.bbr.2024.115280. Epub ahead of print. PMID: 39368713.
Kumar A, Mehan S, Tiwari A, Khan Z, Gupta GD, Narula AS, Samant R. Magnesium (Mg2+): Essential Mineral for Neuronal Health: From Cellular Biochemistry to Cognitive Health and Behavior Regulation. Curr Pharm Des. 2024 Aug 27. doi: 10.2174/0113816128321466240816075041. Epub ahead of print. PMID: 39253923.
Sharma N, Kurmi BD, Singh D, et al. Nanoparticles toxicity: an overview of its mechanism and plausible mitigation strategies. J Drug Target. Published online February 19, 2024. doi:10.1080/1061186X.2024.2316785
Giri, A., Mehan, S., Khan, Z., Das Gupta, G., Narula, A. S., & Kalfin, R. (2024). Modulation of neural circuits by melatonin in neurodegenerative and neuropsychiatric disorders. Naunyn-Schmiedeberg's archives of pharmacology, 10.1007/s00210-023-02939-y. Advance online publication. https://doi.org/10.1007/s00210-023-02939-y
Chhabra S, Mehan S. Matrine exerts its neuroprotective effects by modulating multiple neuronal pathways. Metab Brain Dis. 2023 Jun;38(5):1471-1499. doi: 10.1007/s11011-023-01214-6. Epub 2023 Apr 27. PMID: 37103719.
Prajapati A, Mehan S, Khan Z. The role of Smo-Shh/Gli signaling activation in the prevention of neurological and ageing disorders. Biogerontology. 2023 Apr 25. doi: 10.1007/s10522-023-10034-1. Epub ahead of print. PMID: 37097427.
Kumar S, Mehan S, Narula AS. Therapeutic modulation of JAK-STAT, mTOR, and PPAR-γ signaling in neurological dysfunctions. J Mol Med (Berl). 2023 Feb;101(1-2):9-49. doi: 10.1007/s00109-022-02272-6. Epub 2022 Dec 7. PMID: 36478124.
Sherawat K, Mehan S. Tanshinone-IIA mediated neuroprotection by modulating neuronal pathways. Naunyn Schmiedebergs Arch Pharmacol. 2023 Apr 3. doi: 10.1007/s00210-023-02476-8. Epub ahead of print. PMID: 37010572.
Bhalla S, Mehan S, Khan A, Rehman MU. Protective role of IGF-1 and GLP-1 signaling activation in neurological dysfunctions. Neurosci Biobehav Rev. 2022 Nov;142:104896. doi: 10.1016/j.neubiorev.2022.104896. Epub 2022 Oct 1. PMID: 36191807.
Siddiqui EM, Mehan S, Bhalla S, Shandilya A. Potential role of IGF-1/GLP-1 signaling activation in intracerebral hemorrhage. Curr Res Neurobiol. 2022 Sep 10;3:100055. doi: 10.1016/j.crneur.2022.100055. PMID: 36685765; PMCID: PMC9846475.
Goldman L, Siddiqui EM, Khan A, Jahan S, Rehman MU, Mehan S, Sharma R, Budkin S, Kumar SN, Sahu A, Kumar M, Vaibhav K. Understanding Acquired Brain Injury: A Review. Biomedicines. 2022 Sep 2;10(9):2167. doi: 10.3390/biomedicines10092167. PMID: 36140268; PMCID: PMC9496189.
Mehan S, Arora N, Bhalla S, Khan A, U Rehman M, Alghamdi BS, Zughaibi TA, Ashraf GM. Involvement of Phytochemical-Encapsulated Nanoparticles' Interaction with Cellular Signalling in the Amelioration of Benign and Malignant Brain Tumours. Molecules. 2022 Jun 1;27(11):3561. doi: 10.3390/molecules27113561. PMID: 35684498; PMCID: PMC9182026.
Siddiqui, Ehraz & Khan, Andleeb & Mehan, Sidharth & Sahu, Rakesh. (2021). Green Nanoparticles: A Hope for Targeted Delivery of Natural Therapeuticals for the Management of Glioblastoma Multiforme (GBM). 10.1007/978-981-16-4935-6_12.
Jadaun KS, Sharma A, Siddiqui EM, Mehan S. Targeting Abnormal PI3K/AKT/mTOR Signaling in Intracerebral Hemorrhage: A Systematic Review on Potential Drug Targets and Influences of Signaling Modulators on Other Neurological Disorders. Curr Rev Clin Exp Pharmacol. 2022;17(3):174-191. doi: 10.2174/1574884716666210726110021. PMID: 34455956.
Rajdev K, Mehan S. Neuroprotective Methodologies of Co-Enzyme Q10 Mediated Brain Hemorrhagic Treatment: Clinical and Pre-Clinical Findings. CNS Neurol Disord Drug Targets. 2019;18(6):446-465. doi: 10.2174/1871527318666190610101144. PMID: 31187715.
Files coming soon.
selective publications
Almikhlafi MA, Abdallah NA, Kumar A, et al. Exploring Azithromycin's Neuroprotective Role in Traumatic Brain Injury: Insights into Cognitive and Motor Recovery and Neuroinflammatory Modulation. Pharmaceuticals (Basel). 2025;18(1):115. Published 2025 Jan 16. doi:10.3390/ph18010115
Sangwan M, Chaudhary H, Mehan S, Khan Z, Bahauddin AA, Alrehaili BD, Elbadawy HM, Almikhlafi MA, Narula AS, Kalfin R, Wanas H. Effect of mitochondrial coenzyme-Q10 precursor solanesol in gentamicin-induced experimental nephrotoxicity: Evidence from restoration of ETC-complexes and histopathological alterations. Pharmacol Res Perspect. 2024 Oct;12(5):e70022. doi: 10.1002/prp2.70022. PMID: 39358913; PMCID: PMC11446958.
Ritika, Liao ZY, Chen PY, Rao NV, Mathew J, Sharma R, Grewal AS, Singh G, Mehan S, Liou JP, Pan CH, Nepali K. Rationally designed febuxostat-based hydroxamic acid and its pH-Responsive nanoformulation elicits anti-tumor activity. Eur J Med Chem. 2024 Sep 10;279:116866. doi: 10.1016/j.ejmech.2024.116866. Epub ahead of print. PMID: 39293244.
Singh G, Singh R, Monga V, Mehan S. Thiazolidine-2,4-dione hybrids as dual alpha-amylase and alpha-glucosidase inhibitors: design, synthesis, in vitro and in vivo anti-diabetic evaluation. RSC Med Chem. 2024 Jul 22;15(8):2826-2854. doi: 10.1039/d4md00199k. PMID: 39149094; PMCID: PMC11324062.
Kumar N, Tyagi N, Mehan S, Singh AP. Formulation of Solid Lipid Nanoparticles Loaded with Rosiglitazone and Probiotic: Optimization and In-vitro Characterization. Recent Pat Nanotechnol. Published online January 15, 2024. doi:10.2174/0118722105268801231203144554
Singh G, Singh R, Monga V, Mehan S. 3,5-Disubstituted-thiazolidine-2,4-dione hybrids as antidiabetic agents: Design, synthesis, in-vitro and In vivo evaluation. Eur J Med Chem. 2024;266:116139. doi:10.1016/j.ejmech.2024.116139
Dhiman P, Yadav N, Auti PS, et al. Discovery of thiazolidinedione-based pancreatic lipase inhibitors as anti-obesity agents: synthesis, in silico studies and pharmacological investigations. J Biomol Struct Dyn. Published online February 5, 2024. doi:10.1080/07391102.2024.2310799
Alexova, Ralitza & Alexandrova, Simona & Dragomanova, Stela & Kalfin, Reni & Solak, Ayten & Mehan, Sidharth & Petralia, Maria & Fagone, Paolo & Mangano, Katia & Nicoletti, Ferdinando & Tancheva, Lyubka. (2023). Anti-COVID-19 Potential of Ellagic Acid and Polyphenols of Punica granatum L.. Molecules. 28. 3772. 10.3390/molecules28093772.
Bagang N, Gupta K, Singh G, Kanuri SH, Mehan S. Protease-activated receptors in kidney diseases: A comprehensive review of pathological roles, therapeutic outcomes and challenges. Chem Biol Interact. 2023 May 25;377:110470. doi: 10.1016/j.cbi.2023.110470. Epub 2023 Apr 1. PMID: 37011708.
Seksaria S, Mehan S, Dutta BJ, Gupta GD, Ganti SS, Singh A. Oxymatrine and insulin resistance: Focusing on mechanistic intricacies involve in diabetes associated cardiomyopathy via SIRT1/AMPK and TGF-β signaling pathway. J Biochem Mol Toxicol. 2023 Mar 8:e23330. doi: 10.1002/jbt.23330. Epub ahead of print. PMID: 36890713.
Arora N, Siddiqui EM, Mehan S. Involvement of adenylate cyclase/cAMP/CREB and SOX9/MITF in melanogenesis to prevent vitiligo. Mol Cell Biochem. 2021 Mar;476(3):1401-1409. doi: 10.1007/s11010-020-04000-5. Epub 2021 Jan 3. PMID: 33389492.
Sharma T, Mehan S. Possible Therapeutic Interventions in COVID-19 Induced ARDS by Cotinine as an ACE-2 Promoter and AT-1R Blocker. Infect Disord Drug Targets. 2021;21(6):e170721189261. doi: 10.2174/1871526520666201218153554. PMID: 33342421.
Verma R, Bhatia R, Singh G, Kumar B, Mehan S, Monga V. Design, synthesis and neuropharmacological evaluation of new 2,4-disubstituted-1,5-benzodiazepines as CNS active agents. Bioorg Chem. 2020 Aug;101:104010. doi: 10.1016/j.bioorg.2020.104010. Epub 2020 Jun 16. PMID: 32615464.
Singh L, Rana S, Mehan S. Role of adenylyl cyclase activator in controlling experimental diabetic nephropathy in rats. Int J Physiol Pathophysiol Pharmacol. 2018 Oct 29;10(5):144-153. PMID: 30515257; PMCID: PMC6261921.
Files coming soon.
Research Group
Powered by
This website uses cookies.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.